{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:26:07Z","timestamp":1793316367456,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Cancer immunotherapy represents a novel anticancer strategy that acts directly on the immune system, promoting its activation toward cancer cells to enhance its natural ability to fight cancer. Among various treatments currently used or investigated, chimeric antigen receptors (CAR) T-cell therapy and immune checkpoint inhibitors (ICIs) have consistently proven their efficacy. These innovations are progressively improving the standard of care in cancer treatment, yet they are hampered by novel neurological adverse events, attributing to neurologists a key role in the multidisciplinary oncological team. Indeed, neurotoxicity may develop in up to 77% of patients who received CAR T-cell therapy and usually presents with encephalopathy characterized by a predominant frontal lobe dysfunction. This neurotoxicity is related to cytokine release syndrome, a systemic hyperinflammatory condition triggered by CAR T-cells. On the other hand, following treatment with ICIs, unrestrained T-cells may lead to central and peripheral neurological disorders by antigen-directed autoimmunity. Notably, biological and clinical similarities have been underlined between neurotoxicity related to CAR T-cell therapy and neurological manifestations of cytokine storms (e.g. COVID-19-related encephalopathy), as well as between a subgroup of ICI-related neurological adverse events and paraneoplastic neurological syndromes. Therefore, these cancer immunotherapy-related neurological syndromes may provide an unprecedented, perhaps transitory, opportunity to shed light on the underlying pathogenic mechanisms of a wide spectrum of neurological syndromes and to push forward our knowledge in neuroimmunology.<\/jats:p>","DOI":"10.3389\/fneur.2022.936141","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T05:50:55Z","timestamp":1658209855000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Umberto","family":"Pensato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Muccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-002890corr1","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1212\/CON.0000000000000873","article-title":"Anticancer drugs and the nervous system","volume":"26","author":"Santomasso","year":"2020","journal-title":"Continuum."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science."},{"key":"B6","doi-asserted-by":"publisher","first-page":"E168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"Cells: Continuation in a Revolution of Immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","article-title":"Cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"Cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain."},{"key":"B11","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/acn3.51348","article-title":"Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy","volume":"8","author":"Pensato","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00415-021-10766-5","article-title":"Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity","volume":"269","author":"Pensato","year":"2021","journal-title":"J Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-022-11117-8","article-title":"Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review","author":"Pensato","year":"2022","journal-title":"J Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e3019","DOI":"10.1093\/cid\/ciaa1933","article-title":"SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses","volume":"73","author":"Pilotto","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ana.25855","article-title":"Covid-19-associated encephalopathy and cytokine-mediated neuroinflammation","volume":"88","author":"Muccioli","year":"2020","journal-title":"Ann Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/ene.14491","article-title":"Cytokine release syndrome-associated encephalopathy in patients with COVID-19","volume":"28","author":"Perrin","year":"2021","journal-title":"Eur J Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01184-0.","article-title":"Paraneoplastic autoimmune neurological syndromes and the role of immune checkpoint inhibitors","author":"Duong","year":"2022","journal-title":"Neurotherapeutics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.936141\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T05:50:59Z","timestamp":1658209859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.936141\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":22,"alternative-id":["10.3389\/fneur.2022.936141"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.936141","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"article-number":"936141"}}